President Donald Trump has announced a phased tariff strategy targeting imported generic medicines, giving pharmaceutical companies two years to shift production to the United States before steep duties take effect.
Under the plan, generic drug imports will remain tariff-free beginning Aug. 1, 2026, followed by a 100 percent tariff in August 2028 and a 200 percent tariff in August 2029.
The administration said the policy is designed to encourage manufacturers to build production facilities in the United States.
According to the report, companies that fail to expand domestic manufacturing during the transition period will face the higher import duties.
They cautioned that the move could increase medicine prices and raise the risk of supply shortages.
The report said India, which supplies an estimated 40 to 50 percent of generic prescriptions used in the United States, could be among the countries most affected if manufacturers are unable to establish U.S. operations or secure trade exemptions.
Related Tweet:
Trump threatens 100 percent generic drug tariffs beginning in 2028https://t.co/Ub9p5YSnsY
— The Hill (@thehill) July 22, 2026
Also Read:
TIPP Staff
